The study was positive, and consequently, the Stride regimen is now a standard first-line therapy option for patients with advanced unresectable hepatocellular carcinoma. The 5-year survival results ...

Today, calling Islam a religion seems like the most natural thing in the world. The phrase adorns university handbooks, ...

Formula 1 is back on track. Today, Saturday, October 3, it's time for the final free practice session and qualifying for the Bahrain GP in Malaysia, the sixteenth round of the season. At the Sepang ...

A new study identified more than 1 million people taking weight-loss drugs without any apparent medical reason to do so. By Dani Blum A large new study confirms what many people have long suspected: A ...

Greetings to all my loyal and new readers. Today we have a unique Bible study: an interview with world-renowned sculptor Timothy Schmalz. You may not recognize his name, but you have likely seen his ...

AI engineers often recognize ethical risks associated with the systems they build, but many lack the authority, incentives and organizational support needed to act on them, according to new research ...

"Selena" is CCSU's "synthetic human" that was showcased introducing CCSU President Zulma Toro during a campus technology and AI kickoff event in 2025. Credit: Timothy Scott What does it mean for a ...

As workers’ compensation case managers, we make decisions every day that can significantly affect an injured worker’s life. We coordinate care, communicate with providers, work with employers and ...

For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10 to 15% or ...

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. Researchers found that patients who used the drugs, sold under brand ...

Shortages of the GLP-1 receptor agonists tirzepatide and semaglutide resolved in December 2024 and February 2025, respectively. A secret shopper study found that the majority of weight-loss clinics ...

Watch out, metastatic ER+/HER2- breast cancer. There’s a new targeted agent in town. On Tuesday, the U.S. Food and Drug Administration approved the drug gedatolisib, a multi-targeted kinase inhibitor ...